EUVIMEDEUVIMED entdecken
Open Access

Synthesis, Structure–Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein–Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4

Chandra Bhushan Mishra, Xin Li iD, Bala Krishna Moku, Sehun Kwak, Dnyaneshwar N Garad, Yongcheng Song iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Chandra Bhushan Mishra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, Unite…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Methyltransferases, Nuclear Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mixed lineage leukemia (MLL) gene rearrangements cause ∼75% of acute leukemia in infants and 5-10% in children and adults with poor clinical outcomes. Protein-protein interactions (PPI) between frequent MLL fusion partners AF9/ENL and AF4 or histone methyltransferase DOT1L are drug targets for MLL-rearranged (MLL-r) leukemia. Sixty-seven quinoxiline compounds were synthesized and tested for their ability to inhibit such PPIs. Compounds 16, 17, 59, and 63 were found to be potent inhibitors with IC50 values of 0.35-1.5 μM. Structure-activity relationships are discussed. Potent inhibitors can suppress the expression of MLL target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells with EC50 values as low as 0.84 μM. Compound 17 exhibited significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. It also showed favorable pharmacokinetics in mice. These results indicate that compound 17 is a promising pharmaceutical lead for the treatment of MLL-r leukemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMethyltransferasesNuclear ProteinsStructure-Activity RelationshipHumansAnimalsMiceCell Line, TumorHistone-Lysine N-MethyltransferaseCell ProliferationMyeloid-Lymphoid Leukemia ProteinTranscriptional Elongation Factors

Substanzen

Antineoplastic AgentsDOT1L protein, humanMethyltransferasesHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinNuclear ProteinsELL protein, humanTranscriptional Elongation Factors

Autor:innen und Institutionen

  • Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, United States.
  • Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, United States.

ORCID-Profile: Xin Li, Yongcheng Song

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Mishra, C. B., Li, X., Moku, B. K., Kwak, S., Garad, D. N., & Song, Y. (2025). Synthesis, Structure–Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein–Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01587

Vancouver

Mishra CB, Li X, Moku BK, Kwak S, Garad DN, Song Y. Synthesis, Structure–Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein–Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01587

BibTeX
@article{Mishra2025,
  author = {Mishra, Chandra Bhushan and Li, Xin and Moku, Bala Krishna and Kwak, Sehun and Garad, Dnyaneshwar N and Song, Yongcheng},
  title = {Synthesis, Structure–Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein–Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01587}
}
Kostenlos starten →